DOCSLIB.ORG

CATO佳途科技- Cato Research Chemicals Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CATO 现货标准品产品清单 Cato Research Chemicals Inc. 广州佳途科技股份有限公司 CATO Research Chemicals Inc.专注于标准品研发、生产、服务及销 售，率先在中国建立亚洲技术中心实验室，并已通过ISO17034、 药物杂质标准品联系人：黄舒琦 ISO9001体系认证。CATO中国95%以上员工均为本科以上学历，具有高 电话：020-81215950 度专业的化工化学行业经验。 非药物标准品联系人：叶淑明 目前为止，CATO中国已服务超1万家客户，提供的标准品覆盖工业 电话：020-81960175 品、食品、农药残留、兽药残留、环境、药物杂质、天然提取物等领域， E-mail：[email protected] 同时深度支持定制合成。 “扫一扫” 地址：广州市荔湾区西增路63号自编E1-A101A 我们相信，CATO能给您更好的产品及服务！ 关注CATO微信公众号 官网：http://www.cato-chem.com No. 货号 中文名 英文名 CAS号 药物杂质标准品 1 C3D-1016 2-氨基苯酚 2-Aminophenol 95-55-6 2 C3D-1331 门冬氨酸缩合物 (S)-2-((S)-3-Amino-3-carboxypropanamido)succinic acid 60079-22-3 3 C3D-1350 4-氯苯甲酸 4-Chlorobenzoic acid 74-11-3 4 C3D-1447 戊乙奎醚杂质4 Penehyclidine Impurity 4 5422-88-8 5 C3D-1481 氮卓斯汀EP杂质A Azelastine EP Impurity A 613-94-5 6 C3D-1593 氟西汀EP杂质A(盐酸托莫西汀相关化合物A) Fluoxetine EP Impurity A(Atomoxetine Related Compound A) 42142-52-9 7 C3D-1598 瑞巴派特 Rebamipide 90098-04-7 8 C3D-1636 4-甲基苯磺酸异丙酯 Isopropyl 4-Methylbenzenesulfonate 2307-69-9 9 C3D-1724 Methyl (R)-2-amino-2-phenylacetate hydrochloride Methyl (R)-2-Amino-2-Phenylacetate Hydrochloride 19883-41-1 10 C3D-1792 睾酮 Testosterone 58-22-0 11 C3D-1804 1-羟基苯并三唑 1-Hydroxybenzotriazole 2592-95-2 12 C3D-1808 苯甲醇 Benzyl alcohol 100-51-6 13 C3D-1823 2- [4-(溴甲基)苯基]丙酸 2-[4-(Bromomethyl)phenyl]propionic Acid 111128-12-2 14 C3D-1824 甲基-2-氧代环戊烷羧酸 Methyl 2-Oxocyclopentanecarboxylate 10472-24-9 15 C3D-1831 N-(2-甲基-5-硝基苯基)-4-(吡啶-3-基)嘧啶-2-胺 N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine 152460-09-8 16 C3D-1837 L-丙氨酰-L-谷氨酰胺 L-Alanyl-L-glutamine 39537-23-0 17 C3D-1848 1咪唑乙酸 1-Imidazoleacetic Acid 22884-10-2 18 C3D-1852 2,3,4-三甲氧基苯 2,3,4-Trimethoxybenzaldehyde 2103-57-3 19 C3D-1858 3-(氨甲酰甲基)-5-甲基己酸 3-Carbamoymethyl-5-methylhexanoic acid 181289-15-6 20 C3D-1881 2-甲基-5-硝基苯胺 2-Methyl-5-nitroaniline 99-55-8 21 C3D-1886 富马酸单甲酯 Monomethyl Fumarate 2756-87-8 22 C3D-1887 L-天冬氨酰-L-苯基丙氨酸 L-Aspartyl-L-phenylalanine 13433-09-5 23 C3D-1889 DL-高半胱氨酸硫醇内酯盐酸盐 DL-Homocysteinethiolactone Hydrochloride 6038-19-3 24 C3D-1895 苯磺酸 Benzenesulfonic Acid 98-11-3 25 C3D-1902 阿托酸 Atropic Acid 492-38-6 26 C3D-1905 原儿茶醛 Protocatechualdehyde 139-85-5 27 C3D-1907 L-蛋氨酸亚砜 L-Methionine sulfoxide 3226-65-1 28 C3D-1927 对甲苯磺酸乙酯 Ethyl p-Toluenesulfonate 80-40-0 29 C3D-1928 对甲苯磺酸甲酯 Methyl p-Toluenesulfonate 80-48-8 30 C3D-1939 5-羟甲基-2-糠醛 5-Hydroxymethyl-2-furaldehyde 67-47-0 31 C3D-1953 5-硝基-2-糠醛 5-Nitro-2-Furaldehyde 698-63-5 32 C3D-1954 L-胱氨酸 L-Cystine 56-89-3 33 C3D-1955 L-半胱氨酸 L-Cysteine 52-90-4 34 C3D-1956 N,S-二乙酰基-L-半胱氨酸 N,S-Diacetyl-L-cysteine 18725-37-6 35 C3D-1961 替诺福韦艾拉酚胺 TENOFOVIR ALAFENAMIDE 379270-37-8 36 C3D-1983 L(+) - 精氨酸 L(+)-Arginine 74-79-3 37 C3D-1986 二苯基甲醇 Benzhydrol 91-01-0 38 C3D-2042 2-氯-8-环戊基-5-甲基吡啶并[2,3-d]嘧啶-7(8H) - 酮 2-Chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one 1013916-37-4 39 CATOC3D-2051 2-(氯甲基)-4-甲氧基-3,5-二甲基吡啶盐酸盐 Research2-(Chloromethyl)-4-methoxy-3,5-dimethylpyridine Chemicals Hydrochloride Inc.86604-75-3 40 C3D-2053 2,3,5-三甲基吡啶-1-氧化物 2,3,5-Trimethylpyridine-1-Oxide 74409-42-0 41 C3D-2054 4-硝基-2,3,5-三甲基吡啶-N-氧化物 4-Nitro-2,3,5-Trimethylpyridine-N-Oxide 86604-79-7 42 C3D-2055 4-甲氧基-2,3,5-三甲基吡啶氮氧化物 4-Methoxy-2,3,5-trimethylpyride-N-oxide 86604-80-0 43 C3D-2056 2-(乙酰氧基甲基)-4-甲氧基-3,5-二甲基吡啶 2-(Acetoxymethyl)-4-methoxy-3,5-dimethylpyridine 91219-90-8 44 C3D-2067 吡嗪酰胺EP杂质B(吡嗪腈) Pyrazinamide EP Impurity B(Cyanopyrazine) 19847-12-2 45 C3D-2068 吡嗪酰胺EP杂质A(2吡嗪酸) Pyrazinamide EP Impurity A(2-Pyrazinecarboxylic Acid) 98-97-5 46 C3D-2076 烟酸酰肼 Nicotinic Acid Hydrazide 553-53-7 47 C3D-2098 L-亮氨酸 L-Leucine 61-90-5 48 C3D-2106 吡啶羧酸 Picolinic acid 98-98-6 49 C3D-2108 3-Fluorotoluene 3-Fluorotoluene 352-70-5 50 C3D-2125 二甲胺盐酸盐 Dimethylamine hydrochloride 506-59-2 51 C3D-2140 羟甲基-7-氨基头孢烷酸 Hydroxymethyl-7-Aminocephalosporanic acid 15690-38-7 52 C3D-2154 L-谷氨酸 L-Glutamic Acid 56-86-0 53 C3D-2180 异喹啉 Isoquinoline 119-65-3 54 C3D-2185 盐酸肾上腺素·X水合物 Adrenalone Hydrochloride ·XHydrate 62-13-5 55 C3D-2187 1,1-环丁烷二羧酸 1,1-Cyclobutanedicarboxylic Acid 5445-51-2 56 C3D-2221 尿苷 Uridine 58-96-8 57 C3D-2264 3-羟基-4-甲氧基苯乙胺盐酸盐 3-Hydroxy-4-Methoxyphenethylamine Hydrochloride 645-33-0 58 C3D-2265 2-甲氧基-4-(2-氨基乙基)苯酚 3-O-Methyldopamine Hydrochloride 1477-68-5 59 C3D-2268 高藜芦胺 3,4-Dimethoxyphenethylamine 120-20-7 60 C3D-2273 天冬氨酸天冬氨酸 Aspartylaspartic Acid —— 61 C3D-2277 甲磺酸甲酯 Methyl Methanesulfonate 66-27-3 62 C3D-2278 甲磺酸乙酯 Ethyl Methanesulfonate 62-50-0 63 C3D-2296 吲唑-3-甲酸 3-Carboxyindazole 4498-67-3 64 C3D-2306 3,4-二甲氧基苯丙酸 3,4-Dimetho3-(3,4-Dimethoxyphenyl)propionic acid 2107-70-2 65 C3D-2307 Melphalan EP Impurity K ( Diethylamine ) Melphalan EP Impurity K ( Diethylamine ) 109-89-7 66 C3D-2311 (R)-1-苯基-3-氯-1-丙醇 (R)-3-Chloro-1-phenyl-1-propanol 100306-33-0 67 C3D-2318 (R,R)-2,8-二氮杂双环[4,3,0]壬烷 Cis-Octahydropyrrolo[3,4-b]Pyridine 147459-51-6 68 C3D-2339 甘油 Glycerol 56-81-5 69 C3D-2342 3-氯-1,2-丙二醇 3-Chloro-1,2-propanediol 96-24-2 70 C3D-2359 L-酪氨酸 L-tyrosine 60-18-4 (S)-5-amino-2-((S)-2-amino-3- 71 C3D-2376 (S)-5-amino-2-((S)-2-amino-3-carboxypropanamido)pentanoic acid —— carboxypropanamido)pentanoic acid (S)-2-amino-5-((S)-2-amino-3- 72 C3D-2377 (S)-2-amino-5-((S)-2-amino-3-carboxypropanamido)pentanoic acid —— carboxypropanamido)pentanoic acid 73 C3D-2382 2-叔丁基-4-羟基茴香醚 2-Tert-Butyl-4-Hydroxyanisole 88-32-4 74 C3D-2390 4-羟基异邻苯二甲酸二甲酯 Dimethyl 4-Hydroxyisophthalate 5985-24-0 75 C3D-2402 4,4,4-三氟-1-(对甲苯基)-1,3-丁二酮 4,4,4-Trifluoro-1-(p-tolyl)-1,3-butanedione 720-94-5 76 C3D-2420 托品酸 Tropic Acid 552-63-6 77 C3D-2430 苯肼盐酸盐 Phenylhydrazine Hydrochloride 59-88-1 78 C3D-2455 2-呋喃甲酸 2-Furancarboxylic Acid 88-14-2 79 C3D-2458 2-硝基苯甲醛 2-Nitrobenzaldehyde 552-89-6 80 C3D-2459 N-甲基-D-葡糖胺 N-Methyl-D-Glucamine 6284-40-8 81 C3D-2481 N-甲基邻苯二甲酰亚胺 N-Methylphthalimide 550-44-7 82 C3D-2483 苯磺酸乙酯 Ethyl Benzenesulfonate 515-46-8 83 C3D-2484 3-氨基苯甲酸 3-Aminobenzoic Acid 99-05-8 84 C3D-2485 3-硝基水杨酸 3-Nitrosalicylic Acid 85-38-1 85 C3D-2507 N-乙基-2,3-二酮哌嗪 N-Ethyl-2,3-dioxopiperazine 59702-31-7 86 C3D-2515 O-甲基-L-酪氨酸 O-Methyl-L-tyrosine 6230-11-1 87 C3D-2524 N-(2,6-二氯苯基)-N-苯基-氯乙酰胺 2-Chloro-N-(2,6-dichlorophenyl)-N-phenylacetamide 15308-01-7 88 C3D-2525 2,6-二氯二苯胺 N-(2,6-Dichlorophenyl)aniline 15307-93-4 89 C3D-2532 焦棓酸 Pyrogallol 87-66-1 90 C3D-2534 2,6-二氯苯酚 2,6-Dichlorophenol 87-65-0 91 C3D-2535 3,5-二氯苯胺 3,5-Dichloroaniline 626-43-7 92 C3D-2547 间苯二酚 Resorcinol 108-46-3 93 C3D-2553 二氯乙酸 Dichloroacetic Acid 79-43-6 94 C3D-2569 5-氯噻吩-2-碳酰氯 5-Chlorothiophene-2-carbonyl Chloride 42518-98-9 95 C3D-2577 托品醇 Tropanol 120-29-6 96 C3D-2578 Dimethyl Sulfate Dimethyl Sulfate 77-78-1 97 C3D-2590 乙酸 Acetic Acid 64-19-7 98 C3D-2601 水杨醛吖嗪 Salicylaldehyde Azine 959-36-4 99 C3D-2630 L-丝氨酸 L-Serine 56-45-1 100 C3D-2634 亚氨基二乙酸 Iminodiacetic Acid 142-73-4 101 C3D-2638 2,2＇-二硫化二苯并噻唑 2,2＇-Dibenzothiazolyl Disulfide 120-78-5 102 C3D-2649 2-氯苯甲醛 2-Chlorobenzaldehyde 89-98-5 103 C3D-2652 苯磺酸甲酯 Methyl Benzenesulfonate 80-18-2 104 CATOC3D-2667 Research3,4-二甲氧基苯甲酸 Chemicals3,4-Dimethoxybenzoic Acid Inc.93-07-2 105 C3D-2684 (R)-(+)-1-苯乙胺 (R)-(+)-1-Phenylethylamine 3886-69-9 106 C3D-2690 异烟酸乙酯 Ethyl Isonicotinate 1570-45-2 107 C3D-2697 2-氨基-2-(4-羟基苯基)乙酸 2-Amino-2-(4-hydroxyphenyl)acetic acid 938-97-6 108 C3D-2699 N-亚硝基二乙胺 N-Nitroso-Diethylamine 55-18-5 109 C3D-2726 3-Chloroaniline 3-Chloroaniline 108-42-9 110 C3D-2739 Nitrobenzene Nitrobenzene 98-95-3 111 C3D-2748 4-乙基苯邻二酚 4-Ethylcatechol 1124-39-6 112 C3D-2752 胞苷 Cytidine 65-46-3 113 C3D-2758 4-羟甲基-5-甲基咪唑 4-Hydroxymethyl-5-methylimidazole 29636-87-1 114 C3D-2759 苯磺酸异丙酯 Isopropyl benzenesulfonate 6214-18-2 115 C3D-2760 苯磺酸丙酯 Propyl benzenesulfonate 80-42-2 116 C3D-2764 苯甲酸异戊酯 Isoamyl Benzoate 94-46-2 117 C3D-2766 2,3-二甲氧基苯甲醛 2,3-Dimethoxybenzaldehyde 86-51-1 118 C3D-2770 吡咯-2-甲醛 Pyrrole-2-carboxaldehyde 1003-29-8 119 C3D-2778 磷酸三乙酯 Triethyl Phosphate 78-40-0 120 C3D-2804 2,6-二甲基苯胺盐酸盐 2,6-Dimethylaniline hydrochloride 21436-98-6 121 C3D-2807 L-lysyl-L-lysine L-lysyl-L-lysine 13184-13-9 122 C3D-2809 吡嗪 Pyrazine 290-37-9 123 C3D-2810 5-甲基-2-糠醛 5-Methyl-2-furaldehyde 620-02-0 124 C3D-2820 D-瓜氨酸 D-Citrulline 13594-51-9 125 C3D-2855 D-赖氨酸 D-Lysine 923-27-3 126 C3D-2860 D-对羟基苯甘氨酸甲酯盐酸盐 (R)-Methyl 2-Amino-2-(4-Hydroxyphenyl)Acetate Hydrochloride 57591-61-4 127 C3D-2888 尼泊金异丁酯 Isobutylparaben 4247-02-3 128 C3D-2911 D-缬氨酸 D-Valine 640-68-6 129 C3D-2933 L-2-苯甘氨酸 H-Phg-OH 2935-35-5 130 C3D-2971 2-氯-3-噻吩甲酸 2-Chlorothiophene-3-carboxylic acid 53935-71-0 131 C3D-2973 2-甲基吡嗪 2-Methylpyrazine 109-08-0 132 C3D-2974 N-亚硝基-N-甲基-4-氨基丁酸(异构体混合物） N-Nitroso-N-Methyl-4-Aminobutyric Acid (Mixture of Isomers) 61445-55-4 133 C3D-2980 N-乙酰-L-亮氨酸 N-Acetyl-L-leucine 1188-21-2 134 C3D-2995 2,5-二甲氧基苯甲醛 2,5-Dimethoxybenzaldehyde 93-02-7 135 C3D-2996 甲醇 Methanol 67-56-1 136 C3D-2997 1,4-二甲氧基苯 1,4-Dimethoxybenzene 150-78-7 137 C3D-3040 二苯基羟基乙酸 Benzilic Acid 76-93-7 138 C3D-3060 1-氯乙基环己基碳酸酯 1-Chloroethyl Cyclohexyl Carbonate 99464-83-2 139 C3D-3077 N-亚硝基二丁胺 N-Nitrosodibutylamine 924-16-3 140 C3D-3090 环丙基哌嗪-1-甲酰胺 N-cyclopropylpiperazine-1-carboxamide Hydrochloride 1225500-01-5 141 C3D-3091 甲基哌啶-4-基（丙基）氨基甲酸甲酯 Methyl piperidin-4-yl(propyl)carbamate 1178381-83-3 142 C3D-3092 3-甲氧基苯乙酸 3-Methoxyphenylacetic Acid 1798-09-0 143 C3D-3093 4-甲氧基苯乙酸 4-Methoxyphenylacetic Acid 104-01-8 甲基（R）-3-氨基-2-（（叔丁氧基羰基）氨基）丙酸甲酯 144 C3D-3094 Methyl (R)-3-amino-2-((tert-butoxycarbonyl)amino)propanoate Oxalate 130622-06-9 草酸盐 145 C3D-3105 Fmoc-D-Orn-OH Fmoc-D-Orn-OH —— 146 C3D-3106 Fmoc-NH2 Fmoc-NH2 84418-43-9 147 C3D-3107 Fmoc-CIT-OH Fmoc-CIT-OH 133174-15-9 148 C3D-3108 Fmoc-β-Ala-Cit-OH Fmoc-β-Ala-Cit-OH —— 149 C3D-3134 三甲胺盐酸盐 Trimethylamine Hydrochloride 593-81-7 150 C3D-3135 Fomc-D-瓜氨酸 Fmoc-D-Cit-OH 200344-33-8 151 C3D-3138 3-(三氟甲基)苯甲酸甲酯 Methyl 3-(Trifluoromethyl)benzoate
Recommended publications
  • Meat Biotechnology – Applications in Pork Quality Muscle Targeted Growth Promotants – Mode of Action of Beta Agonists

    Meat Biotechnology – Applications in Pork Quality Muscle Targeted Growth Promotants – Mode of Action of Beta Agonists

    Meat Biotechnology – Applications in Pork Quality Muscle Targeted Growth Promotants – Mode of Action of Beta Agonists Deana Hancock, Diane Moody, Dave Anderson Elanco Animal Health Reciprocal Meat Conference, June 19, 2006 Pharmacological Activity: Beta•Adrenergic Agonist What is a beta•adrenergic agonist? A beta•adrenergic agonist (b•agonist) binds to and activates beta•adrenergic receptors (b•AR) that are found on the surface of many different types of cells in the body. G A G M L V L V G P A A A L P D G Beta Adrenergic P G L E N S S A S A T A N D P V L R A Y Receptors L L P L C K P A S P S R C P A P R C A A D S E F E S D E Y G V R E P W S S E P L T H L S R F E Q Q N F V W G F A R A P T W C R A K D A E L W Y V R G V V I W A V L (1) M (3) W H (5) I N (7) F G T T S L A L L G A S L M A F V M F V S F F A D I N L P V V P V F V L Shaded AA's are V I L C L F S V L P L W Transmembrane L G L S F V T Y W G conserved across the L I M A V L V P C Y A Domains V L A L V E I S S G A S A D A I S I C L V F T N human b1, b2 and b3 T L M A N A L W V A G M F AR's (31%) V L C V T F I N V M S C V I P I I I V I V Y G A I A L L L I A (2) F L L (4) G R (6) T Y K N D R V K C A L R F A R T T G L L C Y R R K S Q C A R R P L A F A R L E Q P D F R K A L T Q A R A E A T Q R R I K P H T L L S A R R D G A H R R T Q R L V A G L V S C Circled AA's are S K P R A L S P P Q K D conserved across F R Y I R A R G D D D D R P D V V G A D K G G N P P S the b AR of S A P G A S T 1 C A E L P humans, pigs, R L L P R P P E A F G N W R and sheep (80%) L A A A A G C G A G G A A A R P A A T D P G P P P S S S L E S K A P D D E P A S V C R F R P P G A P P P S P S P S V A Mersmann, 1998; J.
  • Methods of Isolation and Bioactivity of Alkaloids Obtained from Selected

    Methods of Isolation and Bioactivity of Alkaloids Obtained from Selected

    DOI: 10.2478/cipms-2021-0016 Curr. Issues Pharm. Med. Sci., Vol. 34, No. 2, Pages 81-86 Current Issues in Pharmacy and Medical Sciences Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA journal homepage: http://www.curipms.umlub.pl/ Methods of isolation and bioactivity of alkaloids obtained from selected species belonging to the Amaryllidaceae and Lycopodiaceae families Aleksandra Dymek* , Tomasz Mroczek Independent Laboratory of Chemistry of Natural Products, The Chair of Pharmacognosy, Medical University of Lublin, Poland ARTICLE INFO ABSTRACT Received 17 February 2021 Alkaloids obtained from plants belonging to the Amaryllidaceae and Lycopodiaceae Accepted 20 May 2021 families are of great interest due to their numerous properties. They play a very important Keywords: role mainly due to their strong antioxidant, anxiolytic and anticholinesterase activities. Lycopodium sp., The bioactive compounds obtained from these two families, especially galanthamine Narcissus sp., and huperzine A, have found application in the treatment of the common and AChE inhibitors, TLC, incurable dementia-like Alzheimer’s disease. Thanks to this discovery, there has been SPE, a breakthrough in its treatment by significantly improving the patient’s quality of life and PLE, slowing down disease symptoms – albeit with no chance of a complete cure. Therefore, TLC-bioatography. a continuous search for new compounds with potent anti-AChE activity is needed in modern medicine. In obtaining new therapeutic bioactive phytochemicals from plant material, the isolation process and its efficiency are crucial. Many techniques are known for isolating bioactive compounds and determining their amounts in complex samples. The most commonly utilized methods are extraction using different variants of organic solvents allied with chromatographic and spectrometric techniques.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • A Screening Tool for Acetylcholinesterase Inhibitors

    A Screening Tool for Acetylcholinesterase Inhibitors

    RESEARCH ARTICLE Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors 1 1 2 1 Devashree N. Patil , Sushama A. Patil , Srinivas SistlaID , Jyoti P. JadhavID * 1 Department of Biotechnology, Shivaji University, Kolhapur, MS, India, 2 Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, Virginia, United States * [email protected] a1111111111 a1111111111 a1111111111 a1111111111 Abstract a1111111111 Among neurodegenerative diseases, Alzheimer's disease (AD) is one of the most grievous disease. The oldest cholinergic hypothesis is used to elevate the level of cognitive impairment and acetylcholinesterase (AChE) comprises the major targeted enzyme in AD. Thus, acetylcholinesterase inhibitors (AChEI) constitutes the essential remedy for the treat- OPEN ACCESS ment of AD. The study aims to evaluate the interactions between natural molecules and Citation: Patil DN, Patil SA, Sistla S, Jadhav JP AChE by Surface Plasmon Resonance (SPR). The molecules like alkaloids, polyphenols (2019) Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors. and substrates of AChE have been considered for the study with a major emphasis on affin- PLoS ONE 14(5): e0215291. https://doi.org/ ity and kinetics. To better understand the activity of small molecules, the investigation is sup- 10.1371/journal.pone.0215291 ported by both experimental and theoretical approach such as fluorescence, Circular Editor: David A. Lightfoot, College of Agricultural Dichroism (CD) and molecular docking studies. Amongst the screened ones tannic acid Sciences, UNITED STATES showed promising results compared with others. The methodology followed here have Received: September 26, 2018 highlighted many molecules with a higher affinity towards AChE and these findings may Accepted: March 30, 2019 take lead molecules generated in preclinical studies to treat neurodegenerative diseases.
  • Download PDF Flyer

    Download PDF Flyer

    REVIEWS IN PHARMACEUTICAL & BIOMEDICAL ANALYSIS Editors: Constantinos K. Zacharis and Paraskevas D. Tzanavaras eBooks End User License Agreement Please read this license agreement carefully before using this eBook. Your use of this eBook/chapter constitutes your agreement to the terms and conditions set forth in this License Agreement. Bentham Science Publishers agrees to grant the user of this eBook/chapter, a non-exclusive, nontransferable license to download and use this eBook/chapter under the following terms and conditions: 1. This eBook/chapter may be downloaded and used by one user on one computer. The user may make one back-up copy of this publication to avoid losing it. The user may not give copies of this publication to others, or make it available for others to copy or download. For a multi-user license contact [email protected] 2. All rights reserved: All content in this publication is copyrighted and Bentham Science Publishers own the copyright. You may not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit any of this publication’s content, in any form by any means, in whole or in part, without the prior written permission from Bentham Science Publishers. 3. The user may print one or more copies/pages of this eBook/chapter for their personal use. The user may not print pages from this eBook/chapter or the entire printed eBook/chapter for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained from the publisher for such requirements.
  • Clenbuterol Elisa Kit Instructions Product #101219 & 101216 Forensic Use Only

    Clenbuterol Elisa Kit Instructions Product #101219 & 101216 Forensic Use Only

    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology CLENBUTEROL ELISA KIT INSTRUCTIONS PRODUCT #101219 & 101216 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Clenbuterol and/or other metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Clenbuterol ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug- enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
  • That Had Torte I Una Altra Manian Literatura

    That Had Torte I Una Altra Manian Literatura

    THAT HAD TORTE I USUNA 20180016601A1ALTRA MANIAN LITERATURA UNA ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 / 0016601 A1 Qi et al. ( 43 ) Pub . Date: Jan . 18 , 2018 ( 54 ) METHODS FOR MODULATING GENOME C12N 15 / 10 (2006 .01 ) EDITING A6IK 38 / 46 ( 2006 .01 ) A61K 31 /365 (2006 .01 ) ( 71) Applicants: The Board of Trustees of the Leland A61K 31/ 63 ( 2006 .01 ) Stanford Junior University , Palo Alto , A61K 31 /513 ( 2006 . 01 ) CA (US ) ; The J . David Gladstone A61K 31 /505 ( 2006 .01 ) Institutes , a Testamentary Trust C12Q 1 / 68 ( 2006 .01 ) established under the Will of J . David C12N 9 / 22 ( 2006 . 01 ) Glads, San Francisco , CA ( US) ; The (52 ) U . S . CI. Regents of the University of CPC . .. - . C12N 15/ 907 ( 2013 .01 ) ; C12Q 1 /68 California , Oakland , CA (US ) ( 2013 . 01 ) ; C12Q 1 /44 ( 2013 .01 ) ; C12N 15 / 1024 (2013 .01 ) ; C12N 9 /22 ( 2013. 01 ) ; ( 72 ) Inventors : Lei S . Qi, Palo Alto , CA (US ) ; Sheng A61K 31/ 365 ( 2013 . 01) ; A61K 31 /63 Ding , Orinda , CA ( US ) ; Chen Yu , San ( 2013 .01 ) ; A61K 31/ 513 ( 2013 . 01 ) ; A61K Francisco , CA (US ) 31/ 505 ( 2013. 01 ) ; A61K 38 /465 (2013 . 01 ) (57 ) ABSTRACT ( 21 ) Appl. No. : 15 / 649, 304 Provided herein are methods and kits for modulating (22 ) Filed : Jul. 13 , 2017 genome editing of target DNA . The invention includes using small molecules that enhance or repress homology - directed Related U . S . Application Data repair (HDR ) and / or nonhomologous end joining (NHEJ ) (63 ) Continuation of application No . PCT /US2016 / repair of double - strand breaks in a target DNA sequence .
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Drug and Medication Classification Schedule

    Drug and Medication Classification Schedule

    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
  • Towards a Molecular Understanding of the Biosynthesis of Amaryllidaceae Alkaloids in Support of Their Expanding Medical Use

    Towards a Molecular Understanding of the Biosynthesis of Amaryllidaceae Alkaloids in Support of Their Expanding Medical Use

    Int. J. Mol. Sci. 2013, 14, 11713-11741; doi:10.3390/ijms140611713 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Towards a Molecular Understanding of the Biosynthesis of Amaryllidaceae Alkaloids in Support of Their Expanding Medical Use Adam M. Takos and Fred Rook * Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Thorvaldsensvej 40, 1871 Frederiksberg, Denmark; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +45-3533-3343; Fax: +45-3533-3300. Received: 28 April 2013; in revised form: 26 May 2013 / Accepted: 27 May 2013 / Published: 31 May 2013 Abstract: The alkaloids characteristically produced by the subfamily Amaryllidoideae of the Amaryllidaceae, bulbous plant species that include well know genera such as Narcissus (daffodils) and Galanthus (snowdrops), are a source of new pharmaceutical compounds. Presently, only the Amaryllidaceae alkaloid galanthamine, an acetylcholinesterase inhibitor used to treat symptoms of Alzheimer’s disease, is produced commercially as a drug from cultivated plants. However, several Amaryllidaceae alkaloids have shown great promise as anti-cancer drugs, but their further clinical development is restricted by their limited commercial availability. Amaryllidaceae species have a long history of cultivation and breeding as ornamental bulbs, and phytochemical research has focussed on the diversity in alkaloid content and composition. In contrast to the available pharmacological and phytochemical data, ecological, physiological and molecular aspects of the Amaryllidaceae and their alkaloids are much less explored and the identity of the alkaloid biosynthetic genes is presently unknown. An improved molecular understanding of Amaryllidaceae alkaloid biosynthesis would greatly benefit the rational design of breeding programs to produce cultivars optimised for the production of pharmaceutical compounds and enable biotechnology based approaches.
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Chapter 260-70 WAC EQUINE MEDICATION PROGRAM

    Chapter 260-70 WAC EQUINE MEDICATION PROGRAM

    Chapter 260-70 Chapter 260-70 WAC EQUINE MEDICATION PROGRAM WAC 12/6/93. Statutory Authority: RCW 67.16.020 and 260-70-500 Definitions applicable to chapter 260-70 WAC. 67.16.040. 84-06-061 (Order 84-01), § 260-70-028, 260-70-510 Equine health and safety. filed 3/7/84.] Repealed by 96-10-001, filed 4/17/96, 260-70-540 Veterinarians' reports. effective 5/18/96. Statutory Authority: RCW 260-70-545 Prohibited practices. 67.16.040. 260-70-550 Medication labeling. 260-70-029 Receiving barn. [Statutory Authority: RCW 67.16.020 260-70-560 Treatment restrictions. and 67.16.040. 84-06-061 (Order 84-01), § 260-70-029, 260-70-570 All horses are subject to inspection. filed 3/7/84.] Repealed by 96-10-001, filed 4/17/96, 260-70-580 Official veterinarian's list. effective 5/18/96. Statutory Authority: RCW 67.16.- 260-70-590 Reporting to the test barn. 040. 260-70-600 Sample collection. 260-70-030 When administration prohibited. [Order 74.1, § 260-70- 260-70-610 Storage and shipment of split samples. 030, filed 5/22/74, effective 7/1/74.] Repealed by 80-01- 260-70-620 Medication restrictions. 072 (Order 79-02), filed 12/24/79. Statutory Authority: 260-70-630 Threshold levels. RCW 67.16.020 and 67.16.040. 260-70-640 Permitted medication. 260-70-031 Reporting to receiving barn. [Statutory Authority: 260-70-645 Anti-ulcer medications. RCW 67.16.020 and 67.16.040. 84-06-061 (Order 84- 260-70-650 Furosemide.